retatrutide phase 2 nejm 2023 obesity trial jastreboff Early data for demonstrates exceptional weight loss results, reaching approximately 21% placebo-adjusted weight loss by week 48. This performance significantly exceeds all other leading medications currently under 𧬠The Future of Weight
Description
GLP-1 is distinct from previous classes of prescription weight loss drugs such as phentermine, as they target essential metabolic pathways
Youll likely see deeper wrinkles, more noticeable skin laxity, and a general loss of facial volume
Its More Than Weight Loss More energy
As part of the efforts, local food companies have been encouraged to produce snacks and beverages that are low in fat and sugar, while schools have been ordered to include more physical fitness classes in their curriculums
